Tribunal Upholds Classification of Oxy-Tetracycline Products as Generic Medicaments

The Tribunal upheld the Ld. Commissioner's classification of Oxy-Tetracycline products under CH 3003.20, dismissing the revenue's appeal. Despite not exactly matching pharmacopoeia names, the products were deemed generic medicaments with names present in the Indian Pharmacopoeia, thus not qualifying as Patent or Proprietary medicaments under CH 3003.10. The judgment emphasizes the importance of medicament names in pharmacopoeias for classification purposes, ensuring consistency and aligning with legal interpretations and precedents.

---

---

Issues Involved:
Classification of medicaments under CH 3003.10 as Patent or Proprietary medicaments or under CH 3003.20 as other medicaments.

Detailed Analysis:

1. Issue of Classification:
The appeal by the revenue challenges the Order-in-Original dropping proceedings against the respondent for manufacturing Oxy-Tetracycline products. The main issue is whether these products fall under CH 3003.10 as Patent or Proprietary medicaments or under CH 3003.20 as other medicaments. The revenue argues that since the product names do not appear in the pharmacopoeia, they should be classified as Patent or Proprietary medicaments. However, the respondent claims that the products are covered under the names Oxy-Tetracycline Hydrochloride IP and Oxy-Tetracycline Capsule, which are listed in the Indian Pharmacopoeia, thus not qualifying as Patent or Proprietary medicaments.

2. Contentions of the Parties:
The revenue contends that any medicament not listed in a pharmacopoeia should be considered as Patent or Proprietary medicaments. On the other hand, the respondent argues that as long as the medicament name appears in any pharmacopoeia, it should not be classified as Patent or Proprietary. Reference is made to the judgment of Commr. of Customs & Central Excise, Indore Vs. Endolabs Ltd supporting this argument.

3. Legal Interpretation:
To determine the classification, the Tribunal examines the definition of 'Patent or Proprietary Medicaments' which specifies that if a medicament's name appears in any pharmacopoeia, it should not be considered as Patent or Proprietary. In this case, Oxy-Tetracycline products are found to have names appearing in the Indian Pharmacopoeia, thus not meeting the criteria for Patent or Proprietary classification. Citing precedents like Endolabs Ltd and Hindustan Biologicals, the Tribunal upholds the Ld. Commissioner's classification under Chapter 3003.20, dismissing the revenue's appeal.

4. Judgment and Conclusion:
The Tribunal concludes that the products in question, despite not verbatim matching the pharmacopoeia names, are generic medicaments with names present in the Indian Pharmacopoeia. Drawing on previous rulings, the Tribunal affirms that the products do not qualify as Patent or Proprietary medicaments under CH 3003.10 but fall under CH 3003.20. Therefore, the impugned order is upheld, and the revenue's appeal is dismissed.

In summary, the judgment clarifies the classification of medicaments based on their names appearing in pharmacopoeias, emphasizing the distinction between Patent or Proprietary and other medicaments under relevant chapters. The decision is supported by legal interpretations and precedents, ensuring consistency in classification practices.

---